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Background: In oncology, an emerging paradigm emphasises molecularly targeted approaches for cancer prevention and
therapy and the use of adjuvant chemotherapeutics to overcome cisplatin limitations. Owing to their safe use, some polyphenols,
such as curcumin, modulate important pathways or molecular targets in cancers. This paper focuses on curcumin as an adjuvant
molecule to cisplatin by analysing its potential implications on the molecular targets, signal transducer and activator of
transcription 3 (STAT3) and NF-E2 p45-related factor 2 (Nrf-2), in tumour progression and cisplatin resistance in vitro and the
adverse effect ototoxicity in vivo.
Methods: The effects of curcumin and/or cisplatin treatment have been evaluated in head and neck squamous cell carcinoma as well as
in a rat model of cisplatin-induced ototoxicity by using immunofluorescence, western blot, and functional and morphological analysis.
Results: This study demonstrates that curcumin attenuates all stages of tumour progression (survival, proliferation) and, by
targeting pSTAT3 and Nrf-2 signalling pathways, provides chemosensitisation to cisplatin in vitro and protection from its ototoxic
adverse effects in vivo.
Conclusions: These results indicate that curcumin can be used as an efficient adjuvant to cisplatin cancer therapy. This treatment
strategy in head and neck cancer could mediate cisplatin chemoresistance by modulating therapeutic targets (STAT3 and Nrf2)
and, at the same time, reduce cisplatin-related ototoxic adverse effects.
Platinum-based agents, such as cisplatin, form the mainstay of
currently used chemotherapeutic regimens for several malignancies
(Armstrong et al, 2006; Galluzzi et al, 2012). Notwithstanding the
immense therapeutic success associated with partial responses or
disease stabilisation, the main limitations to the clinical usefulness
of cisplatin are the incidence of chemoresistance and its adverse
side effects (Galluzzi et al, 2012). Frequently, patients with relapsed
or recurrent disease present resistance to cisplatin (Jacobs et al,
1992; Cullen et al, 2003) and the debilitating side effects such as
progressive irreversible ototoxicity (Langer et al, 2013) characterise
further major limitations to cisplatin dose escalation. Cisplatin
causes a bilateral, symmetric high-frequency hearing loss, often
accompanied by tinnitus, as the dose or number of treatments
increase; this permanent impairment is responsible for commu-
nicative disorders harming further the quality of life of cancer
patients (Rybak et al, 2009; Langer et al, 2013; Fetoni et al, 2014).
Research addressed to overcome cisplatin limitations has been
focused on the development, as an adjuvant therapy, of safe
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molecules able to counteract chemotherapy-associated organ
toxicity and to promote tumour toxicity and chemosensitisation.
It is now widely accepted that: (a) cisplatin apoptogenicity depends
on the formation of ROS and that apoptogenic oxidative stress is
the crucial mechanism of both cisplatin-induced cancer cell death
(Berndtsson et al, 2007) and damage to vulnerable normal
cells (Wondrak, 2009); (b) one of the major systems used by both
normal and cancerous cells to counteract oxidative insult is
the NF-E2 p45-related factor 2 (Nrf-2) transcriptionally regulated
program (Hayes and McMahon, 2009; Wondrak, 2009; Singer et al,
2015); (c) JAK-STAT (Janus kinase-STAT) pathway contributes to
tumour cell proliferation and survival, tumour invasion
and angiogenesis (Johnston and Grandis, 2011; Yu et al, 2014).
Thus, the identification of adjuvant redox therapeutics targeting
Nrf-2 and STAT3 constitutes the most rational approach for
prevention of chemoresistance and of chemotherapy-associated
organ toxicity.
As adjuvant chemotherapeutics, selective pro-oxidant redox
intervention that substantially increases cellular ROS and
modulates specific redox-sensitive targets can be achieved using
small-molecule electrophiles containing a Michael acceptor
pharmacophore contained in natural products (Wondrak, 2009).
Indeed, nutraceuticals have gained notable interest as viable
candidates and the polyphenol curcumin has been studied for
the past few decades, with encouraging outcomes, for the
antinflammatory, antioxidant, antiproliferative and preventive
actions (Aggarwal et al, 2004; Thangapazham et al, 2006;
Strimpakos and Sharma, 2008; Goel and Aggarwal, 2010; Zhou
et al, 2011). Curcumin is able to influence multiple intracellular
pathways and its pro-oxidant or antioxidant effects depend,
however, on the concentration of the compound as recently
demonstrated by our group in cisplatin-induced ototoxicity (Fetoni
et al, 2014). Curcumin is considered a potential hormetin, a
coinducer at low doses of heat-shock protein and a direct inducer
of heme oxygenase-1 (HO-1), a well-known marker of intracellular
stress defence system, and at high doses a cellular growth inhibitor
(Calabrese et al, 2008; Demirovic and Rattan, 2013).
On such basis, this research was conceived to explore the pro-
oxidant potential of curcumin as a chemotherapeutic adjuvant
targeting in vitro the transcription factors involved in tumour
progression and cisplatin resistance, STAT3 and Nrf-2, and the
antioxidant curcumin activity by analysing in vivo the protective
molecular changes in a model of chemotherapy organ toxicity to
further investigate the role of the Nrf-2/HO-1 defence system in
healthy cells undergoing a stressful condition. Namely, the
combinatorial strategy was tested in: (1) the head and neck
squamous cell carcinoma (HNSCC) that represents a significant
clinical problem and unsatisfactory long-term survival of patients
(Camacho-Alonso et al, 2013) and (2) the in vivo model of
cisplatin-induced ototoxicity, a well-known adverse effect fre-
quently associated with head and neck cancer treatments. Finally,
to distinguish between the pro-oxidant and antioxidant curcumin
effects and to mimic a possible treatment dosage to be reached in
systemic tissues, we used, both in in vitro and in vivo experiments,
different curcumin doses considering that the therapeutic use
of curcumin has been limited owing to its poor bioabsorption
(Kumar et al, 2014; Prasad et al, 2014).
MATERIALS AND METHODS
Chemicals. Common laboratory chemicals were from Sigma-
Aldrich (Milan, Italy), unless differently stated. Antibodies used are
listed below in methods where appropriate.
Refer to Supplementary Materials for details of experimental
procedures.
In vitro experiments
Cell line. We used PE/CA-PJ15 human oral squamous carcinoma
cell line (European Collection of Cell Cultures) cultured in
Iscove’s modified Dulbecco’s modified Eagle’s medium (DMEM)
(IMDM) supplemented with 10% foetal bovine serum (Biochrom,
Berlin, Germany), 1% penicillin/streptomycin (10 000 U ml 1/
10 000 mg ml 1; Biochrom) and 1% of L-glutamine 200 mM
(Biochrom) at 37 1C in an atmosphere of 95% oxygen and 5% CO2.
Drug administration. Curcumin (high purity; code: C7727) was
dissolved in 0.5% dimethylsulphoxide (DMSO; code: 34869) and
EtOH and sterile H2O (1 : 1) and the range of administered doses
was 0.5, 1.0, 3.37 and 6.75 mM. Cisplatin (CDDP; code: P4394),
dissolved in sterile saline, was administered at a dose of 1.56 mM.
PE/CA-PJ15 cells were tested in two experimental conditions
detailed in Supplementary Materials. No significant differences
were observed between control (not treated) and control vehicle
cells (data not shown). Cisplatin, curcumin and DMSO were
purchased from Sigma-Aldrich.
Cell survival. To evaluate the toxic effect of curcumin, cisplatin
and the combined drug exposure, 1.0 104 cells per well were fixed
with 4% paraformaldehyde for 15 min, washed two times in
phosphate-buffered saline and then incubated in a solution
containing DAPI (4’,6-diamidino-2-phenylindole; 1 : 1000 in
phosphate-buffered saline 0.1 M) and Triton (TX, 0.1% in
phosphate-buffered saline 0.1 M) for 10 min, light protected and
at room temperature. Condensed cell nuclei were identified by
DAPI labelling.
pSTAT3 and Nrf-2 immunofluorescence. pSTAT3 and Nrf-2
immunofluorescence were performed using primary antibodies
such as rabbit anti-phospho-STAT3 (Tyr705) (Cell Signalling
Technology, Boston, MA, USA) and mouse anti-Nrf-2 (Abcam,
Cambidge, UK), respectively. The secondary antibodies for
pSTAT3 and Nrf-2 were goat anti-rabbit 488 (Alexa Fluor) and
donkey anti-mouse 546 (Alexa Fluor), respectively. DAPI counter-
stained the cell nuclei. Images of pSTAT3- and Nrf-2-immunola-
belled specimens (40 ) were taken by the confocal laser scanning
microscope (TCS-SP2; Leica Microsystem GmbH, Wezlar,
Germany). Immunofluorescence was performed 24, 48 and 72 h
after treatment. However, given that no significant differences were
observed among the three time points, only the results at 24 h are
discussed.
TUNEL assay. Apoptosis was evaluated in PE-CA/PJ15 cultures
with the APO-BrdU TUNEL Assay Kit (Invitrogen, Carlsbad, CA,
USA) 48 h after treatment, according to the manufacturer’s
instructions, as described previously (Piacentini et al, 2008).
Western blot. PE/CA-PJ15 cells (2 106) were trypsinised 48 h
after drug treatment and protein concentration was measured using
a Micro BCA Kit (Pierce, Rockford, IL, USA). Protein expression
was evaluated and documented using UVItec Cambridge Alliance
(Cambridge, UK). The experiments were repeated three times, and
an interexperiment variability of o10% was found.
In vivo experiments
Animals. Male adult Wistar rats (200–250 g, UCSC Laboratories,
Rome, Italy) were used (25 animals, randomised and assigned to
four experimental groups as detailed in Supplementary Materials).
All efforts were made to minimise animal suffering and to reduce
their number, in accordance with the European Community
Council Directive of 24 November 1986 (86/609/EEC). All
procedures were performed in compliance with the Laboratory of
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Animal Care and Use Committee of the Catholic University,
School of Medicine of Rome and were approved by the Italian
Department of Health (Ministero della Salute).
Drug administration. As described previously (Fetoni et al, 2014),
curcumin, dissolved in DMSO, was administered intraperitoneally
at three different doses (100, 200 and 400 mg kg 1 body weight).
Curcumin solution was injected 1 h before cisplatin administration
and once daily for the following 3 days. A single cisplatin dose of
16 mg kg 1 (Fetoni et al, 2014) was delivered intraperitoneally at a
rate of 8 ml h 1 with an infusion pump (Axon Instruments, Foster
City, CA, USA) over 30 min. The animals were hyperhydrated with
saline solution (subcutaneous injection, 15 ml daily) to limit
cisplatin side effects.
Auditory function evaluation
Auditory brainstem responses: We performed auditory brainstem
response (ABR) recordings to identify the acoustic threshold of each
animal for each group (Fetoni et al, 2013, 2014). ABRs were
measured at low (6 kHz), mid (12, 16 and 20 kHz) and high (24 and
32 kHz) frequencies. In all animals, ABRs were assessed bilaterally
before treatment (day 0) to assure normal hearing and reassessed at
all time points (3 and 5 days from treatment onset) to evaluate the
effect of treatments on hearing. PC-controlled TDT System 3
(Tucker-Davis Technologies, Alachua, FL, USA) data acquisition
system with real-time digital signal processing was used for ABR
recording and auditory stimulus generation (tone bursts of pure
tones from 6 to 32 kHz, 1 ms rise/fall time, 10 ms total duration, 20/s
repetition rate). Threshold value was defined as the lowest stimulus
level that yielded a repeatable waveform-based onset.
Distortion product otoacoustic emissions: To determine treatment
effect on OHC function, distortion product otoacoustic emissions
(DPOAEs) were measured unilaterally using an otoacoustic
emission system (Tucker-Davis Technologies, Alachua, FL, USA).
Distortion product otoacoustic emissions were recorded before,
and 3 and 5 days after the onset of treatment per second.
Morphological analyses and cell viability. Rhodamine-phalloidin
(Rh-Ph) staining was used to visualise the stereociliary arrays and
cuticular plates of hair cells (Fetoni et al, 2014), performed at day 5
in 5 cochleae per group. All morphologic observations were
performed with the confocal laser scanning system.
Nrf-2/HO-1 and pSTAT3 immunostainings. Immunostainings
were performed at day 5 in cochlear cryosections to assess and
quantify the endogenous antioxidant response to cisplatin-induced
damage and to evaluate the effect of curcumin supplementation
(Fetoni et al, 2013, 2015). Five cochleae per group were used.
Images were obtained with the confocal laser scanning system. We
acquired confocal Z-stacks in series of 15–20 mm thick to evaluate
the real extent of the nuclear and/or cytoplasmatic HO-1, Nrf2 and
pSTAT3 fluorescence of the organ of Corti and SGNs (Fetoni et al,
2015). Control experiments (negative controls not shown) were
performed by omitting the primary antibody during the processing
of tissues randomly selected across experimental groups.
Statistical analysis. Results are presented as means±s.e.m., and
differences were assessed using analysis of variances (ANOVAs).
Po0.05 was considered significant.
RESULTS
In vitro experiments
Curcumin enhances cisplatin cytotoxicity in PE/CA-PJ15 cells.
Tumour survival and growth of PE/CA-PJ15 cells were evaluated at
24, 48 and 72 h after treatment. Curcumin administration induced
a cytotoxic effect in a dose-dependent manner (upper panel of
Figure 1): (a) 0.5 mM induced a slight cell loss that progressed over
time to reach B20% of cell loss after 48 and 72 h of incubation,
(b) 1.0 mM showed a similar effect, B20% and 25% of cell loss at 48
and 72 h, respectively, (c) with 3.37 mM the cytotoxic effect
increased, causing B40% of cell loss at 72 h, (d) 6.75 mM caused
B60–70% of cell loss at 48 and 72 h, respectively (Figure 1A).
Moreover, low doses of curcumin affected marginally tumour
proliferation at the analysed time points (Figure 1B); whereas
starting from curcumin doses of 3.37–6.75 mM, cell proliferation
was highly affected from 24 to 72 h (Figure 1C–E). The dose-
dependent effects of curcumin on PE-CA/PJ15 were also shown by
signs of cell death, nuclear fragmentation and swelling, by DAPI
staining (Figure 1F–J). The effects of cisplatin monotherapy and of
combined regimen (cisplatinþ curcumin) on PE/CA-PJ15 cells are
shown in Figure 2 (upper panel), and indicate that cisplatin
administration induced cell loss of B20% at 24 h, increasing in
later time points of B55% and 60% after 48 and 72 h, respectively
(Figure 2A). The adjuvant curcumin doses of 0.5 and 1.0mM
determined cell loss of B30%, 40% and 60% at 24, 48 and 72 h,
respectively (Figure 2A). This effect increased with the dose of
3.37 mM causing B35%, 70% and 80% of cell death after 48 and
72 h, respectively (Figure 2A). A marked cytotoxicity was observed
at the adjuvant highest curcumin dose of 6.75 mM, causing cell loss
of B55% after 24 h and of B70% and 90% after 48 and 72 h,
respectively (Figure 2A). With regard to cell proliferation, cisplatin
arrested tumour growth (Figure 2B–E), whereas the adjuvant high
and medium curcumin doses decreased proliferation rate already at
24 h (Figure 2C–E). The adjuvant curcumin doses of 0.5 and 1.0mM
did not modify the effect of cisplatin on cell proliferation
(Figure 2B). In Figure 2F–K, images representative of DAPI
staining illustrate the cytotoxic effects.
Curcumin enhances apoptotic activation: TUNEL assay and Bax
western blotting. The analysis of DNA fragmentation in PE/CA-
PJ15 cells revealed low rates of apoptosis (o5%) in control
cultures (Figures 1K, Q and 2L, R) and no significant differences
were observed in cells exposed for 48 h to 0.5 or 1.0 mM of
curcumin (Figure 1L and M). However, a marked TUNEL
labelling was observed after treatment with high and medium
doses of curcumin, with an increase in the number of apoptotic-
positive cells of B15% and 20%, respectively (Figure 1N, O and Q).
These data were also supported by western blot analysis for Bax
expression. Interestingly, proapoptotic expression of Bax
increased markedly in cells treated with medium and high doses
of curcumin with respect to lower dose treatments and control
cells (Figure 1P). Cisplatin monotherapy induced the activation of
apoptotic processes, with B20% of TUNEL-positive cells (Figure
2M and R). The adjuvant curcumin treatment caused an
enhancement of apoptotic-positive cells in a dose-dependent
manner: the highest effect was observed at 3.37 and 6.75 mM doses,
causing DNA fragmentation in B35–40% of cells (Figure 2P–R).
Collectively, these results illustrate the dose-dependent proapop-
totic effect of curcumin, both in the mono- and combinatorial
chemotherapy.
Curcumin inhibits pSTAT3 signalling. Figure 3 shows pSTAT3
immunofluorescence data. Although in control specimens there
was a clear pSTAT3 labelling in the nucleus and in the cytoplasm
(Figure 3A), the fluorescence decreased progressively by increasing
curcumin doses (Figure 3C, E, G and I). In cisplatin-treated cells,
pSTAT3 labelling was evident in both the cytoplasm and nucleus
(Figure 3B). In the combined treatment, there was a marked
decrease in STAT3 phosphorylation, indicated by a change in
fluorescence localisation, which remained confined inside the
cytoplasm of cells (Figure 3D, F, H and J). This effect was more
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evident when medium and high doses of curcumin were used
(Figure 3H and J), as illustrated by immunofluorescence optical
density analysis (Figure 3U). Taken together, these results indicate
that curcumin potentiates antineoplastic effect of cisplatin by
acting on the inhibition of STAT3 phosphorylation: marked
fluorescence intensity in the cytoplasm but absent in the nucleus
indicated deficient pSTAT3 translocation.
Curcumin combinatorial treatment inhibits Nrf-2 nuclear
translocation. Immunofluorescence data revealed a slight Nrf-2
labelling in control condition (Figure 3K). PE/CA-PJ15 exposed to
different doses of curcumin showed an increase in nuclear Nrf-2
fluorescence, in a dose-dependent manner (Figure 3M, O, Q and
S). Immunofluorescence data of cisplatin monotherapy revealed a
marked raise of Nrf-2 labelling, primarily cytoplasmic (Figure 4L).
Interestingly, the adjuvant curcumin doses caused an increase in
Nrf-2 activation that, however, remained restricted inside the
cytoplasm, without translocation into the nucleus (Figure 3N, P, R
and T). This effect was more evident at medium and high
curcumin doses, as shown also by fluorescence quantification data
(Figure 3V). Thus, these results indicate that, when adminis-
tered in conjunction with cisplatin, curcumin treatment can
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Figure 1. Curcumin influences PE/CA-PJ15 tumour progression and apoptosis. (A–D) Graphs (mean±s.e.m.) showing percentage of cell survival
(A) and tumour progression (B–D) at 24, 48 and 72 h after curcumin treatment. (E) Histogram showing the magnitude of tumour progression
between 24 and 72 h, expressed as the percentage of the ratio of the number of cells counted at 72 and 24 h. *Po0.05; **Po0.001.
(F–J) Representative images of DAPI-stained cells treated with curcumin: changes in morphology are indicated by arrows (swelling) and
arrowheads (nuclear condensation and cellular fragmentation). Scale bar: 20mm. (K–O) Representative images of terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay in PE/CA-PJ15 treated with different curcumin doses. Arrows indicative of apoptotic cells. Scale
bar: 50mm. (P) Western blot for Bax activation. Data are normalised to actin values. (Q) Bar graph shows the mean values (mean±s.e.m.) of
apoptotic cells for each condition; *Po0.05; **Po0.001. Data are representative of three independent experiments; each count performed on 10
fields randomly selected for each experimental condition and each time point.
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In vivo experiments: cisplatin ototoxicity
Curcumin otoprotective effect on auditory function: ABR and
DPOAEs. ABRs were recorded in all animals before (day 0), and 3
and 5 days after drug treatment onset. Baseline ABR thresholds did
not differ among the experimental groups, consistent with previous
data (Fetoni et al, 2014). The ABR data are expressed in terms of
threshold shift that represents the difference between the pre- and
post-treatment values of each animal for each group. Cisplatin
administration induced a threshold elevation of B35–40 dB at
days 3 and 5, respectively, as reported previously (Fetoni et al,
2014) (Figure 4A and B). Treatment with curcumin 200 mg kg 1
decreased cisplatin ototoxicity of B20–25 dB at the same time
points (Figure 4A and B). However, the lower dose of curcumin
(100 mg kg 1) had no effect and the higher dose (400 mg kg 1)
worsened, at day 5, the functional damage induced by cisplatin
(Figure 4A and B). Furthermore, the effect of the combined
treatment on OHC function was tested by DPOAEs in all animals.
Sixteen kHz data (frequency most affected by cisplatin
administration) show a progressive decrease in amplitude in the
cisplatin group, spanning from high to low DPOAE levels (Figure 4C
and D). The largest changes occurred at day 5. Curcumin treatment
(200 mg kg 1) significantly attenuated the decrease of DPOAE
amplitude both at days 3 and 5 (Figure 4C and D). However, both
low (100 mg kg 1) and high (400 mg kg 1) doses of curcumin
failed to protect OHC function (Figure 4C and D).
Curcumin-protective effect in the organ of Corti: morphological
analysis. Figure 4 (lower panel) shows Rh-Ph staining and
cochleogram of Ctrl, cisplatin and cisplatinþ curcumin groups
(200 and 400 mg kg 1). No difference was observed between
cisplatin and cisplatinþ curcumin 100 mg kg 1 groups (data not
shown). Cisplatin administration induced mostly OHC loss, which
was characterised by dark spots, phalangeal scars and disappear-
ance of both cuticular plate and hair bundle in the middle and
basal turns (Figure 4F). Also, OHC count showed B55% of hair
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Figure 2. Curcumin increases cisplatin effect in the combined administration. (A–D) Graphs (mean±s.e.m.) showing percentage of cell survival
(A) and proliferation (B–D) at 24, 48 and 72 h of incubation with cisplatin and curcumin at different doses. (E) Histogram shows the tumour
progression between 24 and 72 h, expressed as a percentage of the ratio of the number of cells counted at 72 and 24 h. *Po0.05, **Po0.001 and
***Po0.0001. (F–K) Representative images of DAPI-stained cells; arrows and arrowheads indicate swelling and nuclear condensation/cellular
fragmentation. Scale bar: 20 mm. (L–Q) Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay showing marked apoptotic-
positive cells after cisplatin treatment (M) and after an adjuvant curcumin treatment (N–Q). (R) Related apoptotic cell count (mean±s.e.m.).
**Po0.001. Data are representative of three independent experiments; each count performed on 10 fields randomly selected for each
experimental condition and each time point.
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group as compared with Ctrl (Figure 4I). In the cisplatinþ
curcumin 200 mg kg 1 group, the survival reached B85% and
95% in the same regions of basal and middle turns, respectively.
Values in cisplatinþ curcumin 400 mg kg 1 group did not differ
significantly from cisplatin group: cell survival of B70% in middle
turn and B50% in basal region. No significant differences were
observed in the apical turn among groups.
Curcumin induces Nrf-2/HO-1 pathway activation. Figures 5 and
6 show representative Z-stack acquisitions of Nrf-2 (left panels) and
HO-1 (right panels) immunostainings in high magnifications (100 )
of the organ of Corti and of SGNs, respectively. In control specimens,
Nrf-2 and HO-1 labelling was slightly displaced in the cytosol in
OHCs (Figure 5A and B) and in SGNs (Figure 6A and B) as shown by
the XZ cross-sections (boxes a1–a3 and b1–b3 in Figures 5 and 6). In
both organ of Corti and SGNs of cisplatin specimens, Nrf-2 (Figures 5
and 6, boxes c1–c3) and HO-1 (Figures 5 and 6, boxes
d1–d3) labelling was mainly localised in the cytoplasm. No differences
were observed with curcumin doses 100 and 400 mg kg 1 as
compared with cisplatin specimens (images not shown). Treatment
with curcumin 200 mg kg 1 induced nuclear translocation of Nrf-2,
as clearly indicated by XZ cross-sections (Figures 5 and 6, boxes
e1–e3). In these specimens, high Nrf-2 fluorescence signal was
detected not only in the cytoplasm but also in the nucleus, both in
OHCs (Figure 5E) and in SGNs (Figure 6E). In parallel, in the same
samples, we observed an overexpression of HO-1 both in the organ of
Corti (Figure 5F) and in SGNs (Figure 6F), confined inside the
cytoplasm (boxes f1–f3). Namely, the enhancement of Nrf-2
expression and its nuclear translocation, observed after curcumin
administration, appears to reflect the upregulation HO-1 protein
expression. Collectively, our data indicate that curcumin can activate,
Nrf-2/HO-1 pathway, and potentiate this endogenous antioxidant
defence mechanism against cisplatin ototoxicity.
Curcumin does not influence STAT3 phosphorylation. In control
samples, STAT3 labelling was faint and mainly localised inside the
cytoplasm. Cisplatin treatment did not modify pSTAT3 fluorescence,
which did not translocate into the nucleus. Also, curcumin treatment
at all doses did not influence STAT3 phosphorylation, which remained
confined inside the cytoplasm, with no differences compared with the
other groups (images not shown). Taken together, these results
indicate that in our model of cisplatin-induced ototoxicity in vivo,
curcumin does not act by targeting pSTAT3 signalling.
DISCUSSION
Our results indicate that curcumin enhances cisplatin activity in
HNSCC cells and provides protection from cisplatin side effects in
the cochlea by targeting differently the transcription factors STAT3
DAPI DAPI
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Ctrl CDDP Ctrl CDDP
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Figure 3. Curcumin prevents pSTAT3 and Nrf2 nuclear translocation when administered in conjunction with CDDP. (A–J) Representative
immunofluorescence images of PE/CA-PJ15 treated with cisplatin and/or curcumin and double stained with DAPI (blue) and anti-pSTAT3 antibody
(green). (K–T) Representative images of PE/CA-PJ15 cells labelled with Nrf-2 (red) and DAPI stained (blue). Scale bar: 20mm. (U–V) Histograms
(mean±s.e.m.) showing optical density quantification in the nucleus and cytoplasm of treated cells for pSTAT3 and Nrf-2 labelling, respectively.
*Po0.05; **Po0.001. Data are representative of three independent experiments; each quantification performed on 10 fields randomly selected
for each experimental condition and each time point.
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and Nrf-2. Additionally, curcumin pro-oxidant effect in cancer
cells and antioxidant action in normal cisplatin-stressed cells can
both be achieved by relatively low doses.
Curcumin’s effect was analysed in the in vitro model of the head
and neck cancer, which often demonstrates significant resistance to
cisplatin, acquired through repeated treatment cycles or as an
inherent characteristic of the cancer (Kelland, 2007; Abuzeid et al,
2011). Curcumin, used as monotherapy at low doses (0.5 and
1.0mM), was able to induce a relatively modest antitumor effect
(B20% increase). Both the antiproliferative and cytotoxic effects
increased with the medium dose (3.37 mM) and were remarkably
magnified at the highest dose (6.75 mM) as shown in Figure 1A–E.
The increasing proapoptotic activation was documented by the
dose-dependent number of TUNEL-positive cells and increased
Bax expression (Figure 1P). As an adjuvant to cisplatin
chemotherapy, curcumin had an overall pro-oxidant activity: the
antitumor effect was increased in a dose-dependent mode and the
medium and high doses induced an intense cytotoxic and
antiproliferative effect (B4-folds higher than cisplatin alone) as
documented by the analysis of effect magnitude and by increased
apoptosis (Figure 2E and L–R). These findings are consistent with
the literature with regard to curcumin antitumor efficacy when
used as monotherapy or as an adjuvant in vitro (Goel and
Aggarwal, 2010; Abuzeid et al, 2011; Camacho-Alonso et al, 2013);
however, translation to in vivo models and to clinical settings may
pose some concerns with regard to poor bioavailability of
curcumin (Cole et al, 2007; Hollborn et al, 2013). The low aqueous
solubility and high degradation velocity of curcumin may indeed
result in suboptimal blood concentrations to achieve the
therapeutic effects (Anand et al, 2007; Naksuriya et al, 2014);
however, it can be remarked that a relevant antitumor effect
in vitro was observed at the low/medium doses of curcumin that
could be more easily reached in vivo to obtain decreased tumour
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Figure 4. Curcumin attenuates the functional and morphological damage induced by CDDP in the cochlea. (A and B) Graphs show the threshold
shift values in dB (mean±s.e.m.) in all experimental groups at day 3 (A) and day 5 (B) from treatment onset. (C and D) DPOAE amplitude measured
at 16 kHz at days 3 and 5, respectively. (E–H) Representative surface preparations of the organ of Corti showing Rh-Ph staining. Asterisks indicate
missing OHCs. (I) Cochleogram data (means±s.e.m.) show significant differences among groups in the middle and basal region of the cochlea at
day 5. Data are representative of three independent experiments; n¼5 animals per group. *Po0.05; **Po0.001.
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2008). In addition, the use of novel curcumin analogues with low
toxicity and good bioabsorption (Kumar et al, 2014) or
nanoparticle curcumin formulations (Ghalandarlaki et al, 2014;
Naksuriya et al, 2014; Prasad et al, 2014; Salehi et al, 2014) offer
promising approaches to overcome bioavailability characteristics
and enhance the therapeutic efficacy of cisplatin in head and neck
cancer patients.
The main objective of this study was, however, to get insights
into the molecular targets of curcumin at different doses and we
found that both pSTAT3 and Nrf-2, expressed in the control
cultures, were, respectively, down- and upregulated in a dose-
dependent manner by curcumin monotherapy. Notably, the effect
of the low doses (0.5 and 1.0 mM) on pSTAT3 was remarkable and
the labelling trend was not so dissimilar as compared with the
medium and high doses. As compared with controls, cisplatin did
not change the nuclear and cytoplasmic pSTAT3 level that was
inhibited by curcumin in the combinatory treatments even at the
dose of 0.5 mM (Figure 3). Signal transducer and activator of
transcription 3 has been shown to be constitutively expressed in
HNSCC both in vitro and in vivo (Grandis et al, 2000; Song and
Grandis, 2000) and B82% of HNSCCs exhibit upregulation of
STAT3 expression (Liu et al, 2008), and enhanced STAT3
expression enhances HNSCC survival (Lee et al, 2008). Over-
expression of STAT3 induces tumours in nude mice (Jing and
Tweardy, 2005) and interruption of STAT3 signalling impedes
cancer cell growth, enhances apoptosis in HNSCC (Leeman-Neill
et al, 2009) and sensitivity to cisplatin in vitro HNSCCs (Gu et al,
2010; Pan et al, 2013; Zhou et al, 2014), underlying its potential as
a therapeutic target in this cancer. Signal transducer and activator
of transcriptions has central roles in cancer and inflammation and
signalling by various STATs, particularly STAT3, is highly
interconnected with nuclear factor-kB (NF-kB) signalling,
recognised as a major pathway responsible for both inflamma-
tion-induced carcinogenesis and antitumour immunity (Karin and
Greten, 2005; Sano et al, 2005; Mantovani et al, 2008; Wang et al,
2008; Lee et al, 2014). It can be speculated that, in our in vitro
experiments, curcumin might interfere with STAT3 signalling even
at low doses either by reducing its nuclear translocation and
downstream activation of a broad array of target genes (Mali, 2015)
or, possibly, by curcumin direct inhibition of NF-kB activation that
occurs mainly via I-kB kinase (IKK)-mediated phosphorylation of
inhibitory molecules (Thangapazham et al, 2006; Shishodia, 2013).
Additionally, curcumin, by exerting its well-known anti-inflam-
matory effects, could hamper the possible cytokine-induced
activation of the JAK-STAT pathway (Lai and Johnson, 2010),
decreasing thus the level of cytoplasmic pSTAT3 and consequent
decrease of its nuclear translocation as observed in our
in vitro experiments (compare pSTAT3 cytoplasmic level of
cisplatin treatment with the combined one in Figure 3U).
Altogether, the STAT3 curcumin targeting may represent a
reliable strategy to increase the HNSCC sensitivity to cisplatin
and STAT3 expression may represent an effective biomarker for
predicting the response to targeting therapy (Kumar et al, 2014;
Zhou et al, 2014).
The effect of curcumin on the other molecular target Nrf-2
in vitro was consistent with the literature data (Strimpakos and
Sharma, 2008). Curcumin increased both cytoplasmic and nuclear
Nrf-2 labelling in cancer cells, the increase was dose-dependent
and the nuclear translocation reached the maximum level at














































































Figure 5. Curcumin potentiates Nrf2/HO-1 expression in the organ of Corti after CDDP treatment. Representative images of high magnification of
the organ of Corti double stained with DAPI (blue) and Nrf2 (red, left panel) or HO-1 (green fluorescence, right panel). Merged images are shown
in A3–F3. XZ and YZ cross-sections in boxes (referred to the dashed lines) from the confocal Z-stack acquisitions show cytosolic or nuclear
fluorescence signal (XZ and YZ boxes; a1, b1, c1, d1, e1, f1: DAPI staining; a2, c2, e2: Nrf-2 fluorescence; b2, d2, f2: HO-1 fluorescence; a3, b3, c3, d3,
e3, f3: merge). Scale bar: 30mm. Data are representative of three independent experiments; n¼5 animals per group.
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nuclear translocation was present in cisplatin-treated cells, but,
interestingly, when curcumin was combined with cisplatin
treatment, cytoplasmic Nrf-2 increased with curcumin increments
and the nuclear translocation decreased. Nuclear Nrf-2 labelling
was faint at a combined curcumin dose of 6.75 mM. Again,
curcumin effect was different, protranslocation in the monotherapy
and translocation inhibitory in the combinatory therapy. NF-E2
p45-related factor 2, a member of the cap ‘n’ collar family of
transcription factors, is a key component of the antioxidant
response element (ARE)-mediated induction of phase 2-detoxify-
ing and antioxidant enzymes (Lee et al, 2014). NF-E2 p45-related
factor 2 is inactive in normal physiologic conditions because of its
binding to the cytosolic protein Keap1. Redox stimulation causes
activation of Nfr-2 and its consequent translocation to the nucleus,
where it binds to ARE. Curcumin not only promotes inactivation
of the Nrf2-Keap1 complex leading to increased Nrf-2 binding to
AREs but it also stimulates HO-1 gene activity (Dinkova-Kostova
et al, 2002; Strimpakos and Sharma, 2008; Shen et al, 2015). The
Nrf2/ARE system is present both in healthy tissues, where it is
involved in defence against chemical stress caused by potentially
toxic compounds, and in cancer cells, where it accounts for the
poor response to antitumor drugs (Hayes and McMahon, 2009;
Tew and Townsend, 2012). Increased Nrf-2 expression has been
extensively studied in patients with several malignancies, including
head and neck cancer (Stacy et al, 2006; Huang et al, 2013). In
these patients, Nrf-2 expression is significantly correlated with
increased proliferation and treatment resistance to cisplatin,
seemingly through the induction of antioxidant genes (Yang
et al, 2011). Cisplatin resistance is a major factor in disease relapse,
and the Nrf-2 translocation inhibitory effect of curcumin as an
adjuvant agent to cisplatin in our in vitro experiments appears
pertinent to a tumour chemosensitisation effect. Similarly and
consistent with the literature (Langer et al, 2013; Waissbluth and
Daniel, 2013; Fetoni et al, 2014), the cisplatin-induced redox-based
modifications detected in our in vivo study of the organ of Corti
determined the expression/activity of the transcription factor Nrf-2
and the consequent upregulation of the antioxidant defence
system, HO-1. On the contrary, the cisplatin adverse effects in
the cochlea were inhibited when curcumin was coadministered:
hearing loss was decreased, apoptosis inhibited and Nrf-2
translocation and HO-1 labelling increased. This effect in vivo
was present at the medium curcumin dose, whereas lower or
higher doses were ineffective or detrimental, data consistent with a
previous work and the potential hormetic activity of curcumin
(Calabrese et al, 2008; Fetoni et al, 2014). Remarkably, in normal
cells undergoing cisplatin insult, curcumin as an adjuvant to
cisplatin increases Nrf-2 activation/translocation and its down-
stream transcription of antioxidant genes, providing thus protec-
tion against the oxidative stress. By contrast, in cancer cells
curcumin combined to cisplatin inhibits Nrf-2 translocation,
providing thus sensitisation to tumour oxidative stress. The
different response to curcumin of cancer and normal cells during
chemotherapy may depend on a combination of factors, including
the metabolism of curcumin in those cells, baseline levels of stress
and their capacities for mitigating oxidative stress as reported
recently for a synthetic small molecule with cancer-selective
antiproliferative and cytotoxic activity (Salipur et al, 2014).
Collectively, curcumin has demonstrated significant properties
in the attenuation of all stages of tumour progression (survival,















































































Figure 6. Curcumin enhances Nrf2/HO-1 activation in SGNs after CDDP treatment. Representative images of high magnification of SGNs
immunolabelled with Nrf2 (red fluorescence, left panel), HO-1 (green fluorescence, right panel) and double stained with DAPI (blue fluorescence).
Merged images are shown in A3–F3. XZ and YZ cross-sections in boxes (referred to the dashed lines) from the confocal Z-stack acquisitions show
cytosolic or nuclear fluorescence signal (XZ and YZ boxes; a1, b1, c1, d1, e1, f1: DAPI staining; a2, c2, e2: Nrf-2 fluorescence; b2, d2, f2: HO-1
fluorescence; a3, b3, c3, d3, e3, f3: merge). Scale bar: 20mm. Data are representative of three independent experiments; n¼5 animals per group.
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pathways, provides chemosensitisation to cisplatin and protection
from its adverse effects. In the perspective of a personalised
approach of cancer therapy, the illustrated beneficial effects of
curcumin as an adjuvant agent to cisplatin offer strong preliminary
data for the justification of clinical studies in humans, possibly by
using novel curcumin drug delivery systems.
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